Warnsignale eines Herzinfarkts, die jeder kennen sollt

Gilles Montalescot is Professor of Cardiology at the Pitié Salpêtrière Hospital in Paris, France, where he heads the Department of Cardiology at the Institute of Cardiology. He is a practicing Interventional Cardiologist and has extensive experience in basic and clinical research. He has been the director of the INSERM research Unit UMRS_1166 on Thrombosis for 10 years.

Dr Montalescot has been an investigator for many of the new drugs developed in the past twenty years as well as for many of the new interventional technologies. Dr Montalescot is a senior scientist and has been the lead investigator of many national or international randomized trials including ADMIRAL, ARMADA, ALBION, STEEPLE, ARCHIPELAGO, ABOARD, ACAPULCO, ATOLL, ARCTIC, ANTARCTIC, ACCOAST, ATLANTIC, AEGEAN, AMERICA, ALBATROS, and the ongoing ATLANTIS, ALPHEUS, ARAMIS, ADRIFT trials.

Dr Montalescot is the Chairman of the ACTION study group, an Academic Research Organization based at Pitié Salpêtrière Hospital in Paris. He has served on several task force committees on antithrombotic drugs and acute coronary syndromes and is the current Chairman of the Stable Coronary Artery disease guidelines of the European Society of Cardiology.

Dr Montalescot has received several awards in his country including the J. Valade Prize from the Fondation de France and the J.Escalle award from the National Academy of Medicine. He is a member of several editorial boards and has published over 600 peer reviewed original articles in journals such as the NEJM, JAMA, Lancet. Internationally, Dr Montalescot has also been an invited speaker at plenary sessions of major congresses such as the European Society of Cardiology, the American College of Cardiology ,and the American Heart Association.

Prof. Marco Valgimigli is an Interventional Cardiologist and Deputy Chief of Cardiology at the Cardiocentro Ticino Institute in Lugano, Switzerland and head of clinical research.  He is Professor of Medicine, Faculty of Biomedical Sciences at Università della Svizzera Italiana, Lugano, Switzerland. 

He obtained his medical degree in 1997 with Summa Cum Laude at the University of Bologna, Italy, and completed his training in internal medicine at the same university (1997-1999). He received a degree in cardiological sciences at the University of Ferrara and a PhD in interventional cardiology at Erasmus Medical Center in Rotterdam.

Prof. Valgimigli is a fellow of the European Society of Cardiology (ESC), he is part of the press committee since 2006 and vice chairman of the EAPCI research committee since 2012. He also took as member of the ESC 2013 STEMI and 2014 Revascularization guidelines. He led as principal investigators more than 20 multicenter clinical trials and served as member, section coordinator or chairperson of multiple European Society of Cardiology (ESC) guidelines.

Prof. Valgimigli has published more than 700 peer-reviewed manuscripts, with research interests spanning from coronary and structural interventions to anti-thrombotics. With an H-index of 118 in Scopus and more than 5000 citations, he has been awarded with the highly Cited Researcher title in the field of medicine since 2017.

Gilles Montalescot is Professor of Cardiology at the Pitié Salpêtrière Hospital in Paris, France, where he heads the Department of Cardiology at the Institute of Cardiology. He is a practicing Interventional Cardiologist and has extensive experience in basic and clinical research. He has been the director of the INSERM research Unit UMRS_1166 on Thrombosis for 10 years.

Dr Montalescot has been an investigator for many of the new drugs developed in the past twenty years as well as for many of the new interventional technologies. Dr Montalescot is a senior scientist and has been the lead investigator of many national or international randomized trials including ADMIRAL, ARMADA, ALBION, STEEPLE, ARCHIPELAGO, ABOARD, ACAPULCO, ATOLL, ARCTIC, ANTARCTIC, ACCOAST, ATLANTIC, AEGEAN, AMERICA, ALBATROS, and the ongoing ATLANTIS, ALPHEUS, ARAMIS, ADRIFT trials.

Dr Montalescot is the Chairman of the ACTION study group, an Academic Research Organization based at Pitié Salpêtrière Hospital in Paris. He has served on several task force committees on antithrombotic drugs and acute coronary syndromes and is the current Chairman of the Stable Coronary Artery disease guidelines of the European Society of Cardiology.

Dr Montalescot has received several awards in his country including the J. Valade Prize from the Fondation de France and the J.Escalle award from the National Academy of Medicine. He is a member of several editorial boards and has published over 600 peer reviewed original articles in journals such as the NEJM, JAMA, Lancet. Internationally, Dr Montalescot has also been an invited speaker at plenary sessions of major congresses such as the European Society of Cardiology, the American College of Cardiology ,and the American Heart Association.

Prof. Marco Valgimigli is an Interventional Cardiologist and Deputy Chief of Cardiology at the Cardiocentro Ticino Institute in Lugano, Switzerland and head of clinical research.  He is Professor of Medicine, Faculty of Biomedical Sciences at Università della Svizzera Italiana, Lugano, Switzerland. 

He obtained his medical degree in 1997 with Summa Cum Laude at the University of Bologna, Italy, and completed his training in internal medicine at the same university (1997-1999). He received a degree in cardiological sciences at the University of Ferrara and a PhD in interventional cardiology at Erasmus Medical Center in Rotterdam.

Prof. Valgimigli is a fellow of the European Society of Cardiology (ESC), he is part of the press committee since 2006 and vice chairman of the EAPCI research committee since 2012. He also took as member of the ESC 2013 STEMI and 2014 Revascularization guidelines. He led as principal investigators more than 20 multicenter clinical trials and served as member, section coordinator or chairperson of multiple European Society of Cardiology (ESC) guidelines.

Prof. Valgimigli has published more than 700 peer-reviewed manuscripts, with research interests spanning from coronary and structural interventions to anti-thrombotics. With an H-index of 118 in Scopus and more than 5000 citations, he has been awarded with the highly Cited Researcher title in the field of medicine since 2017.